In April, Opthea revealed that it would be reducing its headcount by 65% as it reels from two discontinued Phase III studies, but on Aug. 18, the Australian biotech revealed that the cuts would be steeper, affecting more than 80% of its employees.
https://www.biospace.com/biospace-layoff-tracker